ProQR Therapeutics (NASDAQ:PRQR – Get Free Report) and Longeveron (NASDAQ:LGVN – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, risk, valuation, dividends and analyst recommendations.
Insider and Institutional Ownership
32.7% of ProQR Therapeutics shares are held by institutional investors. Comparatively, 10.0% of Longeveron shares are held by institutional investors. 8.4% of ProQR Therapeutics shares are held by insiders. Comparatively, 7.4% of Longeveron shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Profitability
This table compares ProQR Therapeutics and Longeveron’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| ProQR Therapeutics | -223.51% | -73.83% | -35.14% |
| Longeveron | -1,977.59% | -223.19% | -150.20% |
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| ProQR Therapeutics | 1 | 1 | 6 | 0 | 2.62 |
| Longeveron | 1 | 1 | 1 | 0 | 2.00 |
ProQR Therapeutics currently has a consensus target price of $7.50, indicating a potential upside of 354.55%. Longeveron has a consensus target price of $80.00, indicating a potential upside of 2,746.98%. Given Longeveron’s higher probable upside, analysts clearly believe Longeveron is more favorable than ProQR Therapeutics.
Risk & Volatility
ProQR Therapeutics has a beta of 0.06, indicating that its share price is 94% less volatile than the S&P 500. Comparatively, Longeveron has a beta of -0.25, indicating that its share price is 125% less volatile than the S&P 500.
Earnings and Valuation
This table compares ProQR Therapeutics and Longeveron”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| ProQR Therapeutics | $17.99 million | 9.66 | -$47.73 million | ($0.46) | -3.59 |
| Longeveron | $1.20 million | 7.47 | -$22.70 million | ($9.90) | -0.28 |
Longeveron has lower revenue, but higher earnings than ProQR Therapeutics. ProQR Therapeutics is trading at a lower price-to-earnings ratio than Longeveron, indicating that it is currently the more affordable of the two stocks.
Summary
ProQR Therapeutics beats Longeveron on 11 of the 14 factors compared between the two stocks.
About ProQR Therapeutics
ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Rett syndrome; AX-2911 for nonalcoholic steatohepatitis (NASH); AX-0601 for obesity and Type 2 diabetes; and AX-9115 for rare metabolic condition, as well as various other targets. In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center; Inserm Transfert SA; Ionis Pharmaceuticals, Inc.; Vico Therapeutics B.V.; University of Rochester; and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.
About Longeveron
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company’s lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors. It is conducting Phase 1, Phase 1/2, Phase 2a, and Phase 2b clinical trials in various indications, such as aging-related frailty, alzheimer’s disease, and hypoplastic left heart syndrome. Longeveron Inc. was incorporated in 2014 and is headquartered in Miami, Florida.
Receive News & Ratings for ProQR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
